i+Med | Drug products

i+Med | Drug products

Developer and manufacturer of new drug products with control realease technologies.

About the plant

About the Company

Founded in 2014, i+Med is a technology-based cooperative specializing in the research, development, and manufacturing of advanced biomedical technologies and controlled drug delivery systems.

Today, i+Med has established itself as a benchmark in smart biomaterials and personalized nanohydrogels, with a presence in international markets. Our essence defines us, but our commitment goes even further: to revolutionize personalized medicine through innovative solutions that enhance people s quality of life.

i+Med CDMO

CONTROLLED DRUG DELIVERY TECHNOLOGIES & SMART NANOHYDROGELS

• Smart hydrogels responsive to stimuli.
• Long-acting drug delivery systems for medical and cosmetic applications.
• Nanotechnology applied to drug administration.
• Development of customized formulations for various therapeutic areas.

BIOCOMPATIBILITY & NANOMEDICINE

• Biomimetic materials tailored to patient needs.
• Preclinical testing for biocompatibility validation.
• Clinical trials for product validation.
• Comprehensive project support, from formulation to product certification, with options for manufacturing or technology transfer.

PHARMACEUTICAL QUALITY & TECHNOLOGICAL CAPABILITIES

• State-of-the-art facilities with flexible manufacturing capacity.
• Development and production of biomaterials in compliance with international regulations.
• GMP certifications and European quality standards for the manufacturing of medical and cosmetic products.

COLLABORATION MODELS

Development

• Design and optimization of advanced formulations.
• Preclinical evaluation and biocompatibility characterization.
• GMP-compliant manufacturing for clinical trials.
• Small- and medium-scale production with a focus on flexibility and quality control.

Manufacturing

• Scalability assessment and process optimization.
• Large-scale production with technology transfer.
• Regulatory support and compliance assurance.
• Customized packaging and distribution solutions aligned with global standards.
• Ensuring product integrity from development to international distribution.

Biomaterials & Pharmaceutical Forms

• Long-acting injectable hydrogels.
• Functionalized nanohydrogels for targeted therapy.
• Advanced formulations for topical and ophthalmic use.
• Transdermal systems and controlled drug release technologies.
• Innovative medical devices tailored to patient needs.
• Finished Dosage Forms (FDF): PFS, Gel, Liquid, Oral, Cream, Drops, etc...

---

Certifications

• ISO

---

Activity

• Implants, Oral liquids and semisolids, Oral solids / OSD, Sterile forms (ophtalmic, nasal, otic), Topical, mucosal and transdermal, Injectables, Bottles, Tubes, Sprays, Bulk, Sachets, Stick packs, Ampoules, Oral solutions, Oral suspensions, Oral emulsions, Syrups, Oral gels, Oral foams, Tablets, Hard capsules, SoftGel capsules, Granules / Pellets, Powders, Lyophilizates, Lozenges, Gummies, Terminal sterilization, Fill&Finish, BFS (Blow-Fill-Seal), Bottles, Dropper bottles, Ophtalmic dispensers, Tubes, Sprays, Semisolid forms, Liquid forms, Patches, Suppositories and vaginal ovules, tablets, capsules, rings, Terminal sterilization, Fill&Finish, Small volume vials, Glass ampoules, PFS (Prefilled Syringes), FDF / DRUG PRODUCTS manufacturing

---

Features

• Uses: Investigational, Preclinical, Phase I, Human
• Toxicity (OEB classification): 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 5 / HPAPI (PDE < 10 µg/day)
• DEA: N/A
• BSL: 1, 2, 3, 4
• Therapeutic areas: (A) Digestive tract and metabolism, (D) Dermatologicals, (M) Musculoskeletal system, (S) Sensory organs, (V06) Nutrients
• Markets: DIGEMID (Peru), COFEPRIS (Mexico), INVIMA (Colombia), MSPAS (Guatemala), ISP (Chile), FDA (USA), EMA (EU), PMDA (Japan), CDSCO (India), Health Canada (Canada), MHRA (UK), TGA (Australia), NMPA (China), EDE (UAE), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), Russian Health Authorities

---

Batch Size / Reactor

• Small, Medium, Large

---

Services

• Regulatory services, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging, Preformulation studies, R&D, Formulation / Galenic design, QbD (Quality by Design), Process development, Process optimization, Process validation, Stability studies design, Stability studies execution, ICH Stability studies, Tech transfer, Formulation mixing, Research batches, Engineering batches, Scale-up, Pilot batches, Registration batches, Batch records, Analytical methods development, Analytical methods validation, Release testing of raw materials, Release testing of product, Analytical methods transfer, Batch certification / release, Primary packaging, Secondary packaging, Labeling, Serialization, CMC regulatory support, IND (Investigational New Drug aplication) filing support, IMPD (Investigational Medicinal Product Dossier) submission support

---